Inhibitory actions of lupinifolin isolated from Derris reticulata stem against carbohydrate-digesting enzymes

Pulbutr, Pawitra; Nantana, Pichnatcha; Suksabai, Surabot; Mudjupa, Chawannuch; Denchai, Rattazart; Rattanakiat, Sakulrat; Dhammaraj, Taweesak

doi:10.4103/pr.pr_117_19

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Isolation of lupinifolin from D. reticulata stem: The purified lupinifolin used in the experiment was obtained from our previous study 13 . The authentication of D. reticulata samples and the isolation of lupinifolin were conducted as previously described in our earlier publication 15 . The isolated lupinifolin was kept at -20EC before using in the experiment.…”

Section: Study Areamentioning

confidence: 99%

Antibiofilm Formation Activity of Lupinifolin Against Methicillin-Resistant Staphylococcus aureus

Rattanakia¹,

Taensantia²,

Jaemamporn³

et al. 2022

Pakistan J. of Biological Sciences

Self Cite

View full text Add to dashboard Cite

Background and Objective: Biofilm formation activity of Methicillin-resistant Staphylococcus aureus (MRSA) is one of the crucial factors rendering this pathogenic bacterium difficult to be eradicated. It has been reported that lupinifolin, is a major phytochemical agent isolated from Derris reticulata Craib. stem possesses antibacterial activity against MRSA. This study aimed to investigate the effects of lupinifolin and its combinations with some antibacterial drugs, including ampicillin, cloxacillin or vancomycin, on the biofilm formation activity of MRSA. Materials and Methods: The crystal violet biofilm formation assay was performed to evaluate the biofilm formation activity. Results: Lupinifolin produced a significant inhibitory activity against MRSA biofilm formation with the median inhibitory concentration (IC 50 ) of 7.96±3.05 µg mLG 1 (n = 6) at 24 hrs incubation. Lupinifolin at the concentrations of sub-MICs (1, 2, 4 and 8 µg mLG 1 ) combined with the antibacterial drugs at their sub-MICs also exhibited substantial antibiofilm formation activities. The maximal antibiofilm activity was found with the combination of lupinifolin (8 µg mLG 1 ) and vancomycin (1 µg mLG 1 ) by the percentage inhibition of 102.39±0.89 (n = 8). The antibiofilm formation activities of the combinations between lupinifolin and the antibacterial drugs at various concentrations tested were also significantly higher than those of lupinifolin alone. Conclusion: These results indicated that lupinifolin can potentially be developed as an antibacterial enhancer for the management of biofilm-associated bacterial infections caused by MRSA, in which the current pharmacological treatment is still limited.

show abstract

Section: Study Areamentioning

confidence: 99%